Riskpilot← Back to searchSign inGet full accessCasa Cure Consulting AB
ABDissolvedOrg 5569478117FalunEngineering activities and related technical consultancy · NACE 7112Est. 20131 employees
Revenue 2024
SEK 33K
EBITDA margin
-127.3%
+82% vs 2023
Equity ratio
86.0%
Financial strength
Net profit 2024
SEK -42K
+39% vs 2023
| Revenue | SEK 33K | — |
| EBITDA | SEK -42K | +82% |
| Net profit | SEK -42K | +39% |
| Total assets | SEK 86K | -70% |
| Equity | SEK 74K | -73% |
| Employees | 1 | — |
Legal name
Casa Cure Consulting AB
Org number
5569478117
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
6 november 2013
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Aktiebolaget ska bedriva konsultverksamhet inom byggentreprenad- branschen och därmed förenlig verksamhet.
Address
Falun
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 269 | 52 | 0 | 0 | 33 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 43 | −132 | −236 | −229 | −42 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 43 | −132 | −236 | −229 | −42 |
| Net financials | −1 | — | — | — | — |
| Profit before tax | 87 | −12 | −23 | −69 | −42 |
| Tax | −21 | −0 | −0 | −0 | −0 |
| Net profit | 66 | −12 | −23 | −69 | −42 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 483 | 1 126 | 519 | 287 | 86 |
| Equity | 945 | 750 | 346 | 277 | 74 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 45 | 3 | 13 | 10 | 12 |
| Total debt | 45 | 3 | 13 | 10 | 12 |
EBITDA margin
-127.3%
This company
15.8%
Market median
-906% vs market
20202024
Equity ratio
86.0%
This company
38.2%
Market median
+125% vs market
20202024
Return on equity
-56.8%
This company
18.4%
Market median
-409% vs market
20202024
Net profit margin
-127.3%
This company
8.1%
Market median
-1672% vs market
20202024
Asset turnover
0.38×
This company
1.12×
Market median
-66% vs market
20202024
Debt / equity
0.16×
This company
0.62×
Market median
+74% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2025 | |
| Deputy Board Member | 2025 | |
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Former (2) | ||
| Board of Directors | 2022 – 2025 | |
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Casa Cure Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Birgitta Killgren Jonsson | Deputy Board Member | 0 companies |
| Inger Margareta Dahle | Deputy Board Member | 0 companies |
| Bo Lars Gunnar Kjellander | Board of Directors | 0 companies |
| Bengt Junior Niklas Nygårds | Deputy Board Member | 0 companies |
| Ulrika Margareta Ahlholm | Board of Directors | 0 companies |
| Anne-Kristin Godöen Kjellander | Deputy Board Member | 0 companies |